We analyzed one assertion on this topic, and it supports the idea that combining semaglutide and PG-110 leads to greater weight loss than semaglutide alone in obese mice, while muscle mass is preserved [1]. What we’ve found so far is limited to this single claim, with no studies contradicting it. The evidence we’ve reviewed leans toward this combination producing more weight loss without muscle loss, but we cannot say how strong or consistent this effect might be across different conditions. There are no other studies in our current review to compare, replicate, or challenge this result. We don’t know if the same outcome would appear in humans, or if the muscle preservation holds under longer-term use or different doses. The term “preserving muscle mass” here refers to the observation that fat loss occurred without a measurable drop in lean tissue, but we don’t have details on how muscle was measured or whether the effect was statistically significant. Because only one assertion exists in our dataset, our analysis remains incomplete. More research would be needed to understand how reliable or generalizable this finding might be. For now, if you’re considering this combination, it’s important to remember that these results come from mice, not people, and no human trials have been included in our review.